ROCHESTER, N.Y., June 30, 2026—CooperVision is helping bring vision care and myopia awareness directly to families in Rochester through a new partnership with The Strong National Museum of Play. As the presenting sponsor of the museum’s “Summer of Exploration” program, CooperVision is supporting interactive experiences designed to educate children and caregivers about the importance of eye health—while also expanding access to care through free vision screenings. With myopia now affecting nearly one in three children globally and rising, early awareness and intervention are more important than ever.†1
As part of this effort, CooperVision will collaborate with the University of Rochester Medicine Flaum Eye Institute to provide complimentary vision screenings for children visiting the museum on July 23 and August 20 from noon to 2 p.m. in the Adams Atrium. The free vision screenings will be conducted by volunteers from University of Rochester Medicine Flaum Eye Institute’s Pediatric MobilEyes program, who will assess children from pre-K to high school for potential vision problems or eye disease.
CooperVision’s summer-long museum exhibit, “The Great Wonder Seekers Adventure,” will feature engaging, family-friendly information on myopia, including the importance of early intervention. Located along the wall in the Adams Atrium, kids will explore myopia simulation boards to experience firsthand the visual challenges associated with myopia and the importance of having clear vision. The installation will also include activity maps containing pictures of eight hidden wonders for children to search and find throughout the museum.
“Rochester isn’t just where we operate, it’s home. We feel a deep responsibility to take care of the children growing up in this community,” said Steven Robins, President, Americas, CooperVision. “Too many children experience vision challenges that go undetected, but we have both the expertise and the opportunity to make a meaningful difference locally. By providing free screenings and delivering engaging, hands-on education directly to families at The Strong, we’re raising awareness and helping ensure that children across Rochester have the clear vision they need to learn, play, and thrive.”
Among CooperVision’s innovations is MiSight® 1 day, the first and only FDA-approved* soft contact lens proven to slow the progression of myopia in children.‡2 The lens is part of CooperVision’s comprehensive portfolio of myopia control and management solutions—the world’s largest evidence-based range of interventions§ designed to address the diverse needs and lifestyles of children with myopia.
“We are proud to partner with CooperVision to bring the Summer of Exploration program at The Strong to life. CooperVision’s support reinforces their exceptional commitment to the community and children’s well-being,” said Hillary Bobys, Senior Director of Corporate and Strategic Relations at The Strong.
To learn more about The Strong’s other summer initiatives, visit http://www.museumofplay.org and to learn more about CooperVision, visit https://coopervision.com/
# # #
About CooperVision
CooperVision, a division of CooperCompanies (Nasdaq:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric, and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life’s beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women’s healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com.
Media Contact
Wendy Boyce
McDougall Communications for CooperVision
wendy@mcdougallpr.com or (585) 752-5805
*Indications for use: MiSight® 1 day (omafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 D to -4.00 D (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
†Based on a comprehensive analysis of 276 studies, involving a total of 5,410,945 children and adolescents with spherical equivalent of -0.50D or less, aged 6-19 from across 50 countries, with notable variations in prevalence across different demographic groups.
‡Compared to a single vision 1 day lens over a 3-year period.
§Based on treatment types and brands. Products available in the U.S. include MiSight® 1 day.
References:
1. Liang J, Pu Y, Chen J, et al, Global prevalence, trend and projection of myopia in children and adolescents from 1990 to 2050: a comprehensive systematic review and meta-analysis, British Journal of Ophthalmology, Published Online First: 24 September 2024.
2. Chamberlain P, et al. A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control. OVS 2019;96:556-567.
19959 06/26